Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in Metastatic Differentiated Thyroid Carcinoma
NCT00061906Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jan 2003
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib oral solution in thyroid carcinoma (TC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Progression-Free Survival at 12 months. Started Jan 2003; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT00061906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061906.